Imawari M, Kita H, Moriyama T, Kaneko T, Hiroishi K
Liver Study Laboratory, Jichi Medical School, Tochigi, Japan.
Princess Takamatsu Symp. 1995;25:221-5.
To clarify whether abnormal cytotoxic T lymphocyte (CTL) responses to hepatitis C virus (HCV) contribute to viral persistence and the development of subsequent chronic liver disease, we studied CTL responses of peripheral blood lymphocytes (PBLs) to HCV in patients with human leukocyte antigen (HLA) B44. CTLs were generated from PBLs by repeated stimulation with a synthetic HCV nucleoprotein peptide. The recognition of the peptide by CTLs was not strong and was restricted by an HLA B44 molecule. The minimal optimal epitope was a 9-mer peptide of HCV nucleoprotein residues 88 to 96. The CTLs also recognized an HCV antigen produced by a recombinant vaccinia virus construct. The CTLs could be induced from PBLs in 4 of 9 patients with past or ongoing HCV infection. Two of the 4 patients who demonstrated the CTL responses had cleared HCV from the circulation. In one of the 4 patients, the infecting strain of HCV was a mutant: this patient's CTLs recognized the variant peptide less efficiently than the wild-type peptide. In the remaining one patient, the amino acid sequence of serum HCV nucleoprotein residues 88 to 96 was that of a wild-type HCV but the titer of HCV RNA in serum was low. All 5 patients who did not demonstrate the CTL responses had high titers of a wild-type HCV in their serum. Thus, insufficient CTL responses to HCV and emergence of HCV variants that escape recognition by CTLs or otherwise prevent the CTL response may contribute to HCV persistence resulting in the subsequent development of chronic liver disease.
为了阐明细胞毒性T淋巴细胞(CTL)对丙型肝炎病毒(HCV)的异常反应是否会导致病毒持续存在以及随后慢性肝病的发展,我们研究了人类白细胞抗原(HLA)B44患者外周血淋巴细胞(PBL)对HCV的CTL反应。通过用合成的HCV核蛋白肽反复刺激从PBL中产生CTL。CTL对该肽的识别不强,且受HLA B44分子限制。最小的最佳表位是HCV核蛋白残基88至96的9肽。CTL还识别重组痘苗病毒构建体产生的HCV抗原。在9例既往或正在感染HCV的患者中,有4例患者的PBL可诱导产生CTL。表现出CTL反应的4例患者中有2例已从循环中清除HCV。在4例患者中的1例中,感染的HCV毒株是突变体:该患者的CTL识别变异肽的效率低于野生型肽。在其余1例患者中,血清HCV核蛋白残基88至96的氨基酸序列为野生型HCV,但血清中HCV RNA滴度较低。所有5例未表现出CTL反应的患者血清中野生型HCV滴度均很高。因此,对HCV的CTL反应不足以及出现逃避CTL识别或以其他方式阻止CTL反应的HCV变异体可能会导致HCV持续存在,从而导致随后慢性肝病的发展。